Search

Karl H Ploessl

from Wilmington, DE
Age ~64
Get Report
Also known as:
Karl Dr Ploessl, Karlh Ploessl, Karl Ploesl
Phone and address:
1525 Delaware Ave, Wilmington, DE 19806
Connected to:
Bryan G Ploetz, 48Danielle M Ploetz, 44Ryan W Ploetz, 34Granis Plog, 102Bruce M Ploger, 60Suzanne K Ploger, 52Robert A Plohetski, 65Craig C Plokhoy, 64Jessica S Plomares, 38Peter Plomchok, 68

Karl Ploessl Phones & Addresses

  • 1525 Delaware Ave, Wilmington, DE 19806
  • 1525 Delaware Ave APT 3, Wilmington, DE 19806
  • Philadelphia, PA
  • Fort Collins, CO

Work

Company: University of pennsylvania Position: Senior research scientist

Education

School / High School: Colorado State University

Skills

Organic Chemistry • Medicinal Chemistry • Chemistry • Organometallic Chemistry • Drug Discovery • Organic Synthesis • Hplc • Nmr • Life Sciences • Science • Biotechnology • Cancer • Oncology • Research • Nuclear Magnetic Resonance • Clinical Trials

Industries

Higher Education

Resumes

Resumes

Karl Ploessl Photo 1

Senior Research Scientist

View page
Location:
Philadelphia, PA
Industry:
Higher Education
Work:
University of Pennsylvania
senior research scientist
Education:
Colorado State University
University of Konstanz
Heidelberg University
Skills:
Organic Chemistry
Medicinal Chemistry
Chemistry
Organometallic Chemistry
Drug Discovery
Organic Synthesis
Hplc
Nmr
Life Sciences
Science
Biotechnology
Cancer
Oncology
Research
Nuclear Magnetic Resonance
Clinical Trials

Publications

Us Patents

Single Diastereomers Of 4-Fluoroglutamine And Methods Of Their Preparation And Use

View page
US Patent:
20120288444, Nov 15, 2012
Filed:
Aug 13, 2010
Appl. No.:
13/389521
Inventors:
Hank F. Kung - Springfield PA, US
Craig B. Thompson - Merion Station PA, US
Wenchao Qu - Ardmore PA, US
Karl Ploessl - Wilmington DE, US
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
International Classification:
C07C 237/06
C07C 231/12
C07C 271/22
A61K 51/04
C07C 309/73
US Classification:
424 189, 558 50, 560 29, 562561
Abstract:
The present invention is directed single diasteromers of 4-fluoroglutamine having a diastereomeric excess of at least 80%. Methods of preparing the single diastereomers are also described, as well as methods of using the single diastereomers of radiolabeled 4-fluoroglutamine as imaging agent is also described.

Novel Deuterium Substituted Positron Emission Tomography (Pet) Imaging Agents And Their Pharmacological Application

View page
US Patent:
20210346526, Nov 11, 2021
Filed:
Jul 26, 2021
Appl. No.:
17/384998
Inventors:
- Philadelphia PA, US
Zhihao ZHA - Philadelphia PA, US
Futao LIU - Philadelphia PA, US
Karl PLOESSL - Wilmington DE, US
Seok Rye CHOI - Aston PA, US
Hank F. KUNG - Springfield PA, US
International Classification:
A61K 51/04
A61B 6/03
C07B 59/00
C07D 221/06
C07D 213/64
C07D 405/04
C07C 217/80
C07D 471/04
C07C 323/37
Abstract:
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Novel Deuterium Substituted Positron Emission Tomography (Pet) Imaging Agents And Their Pharmacological Application

View page
US Patent:
20200230263, Jul 23, 2020
Filed:
Mar 19, 2020
Appl. No.:
16/824139
Inventors:
- Philadelphia PA, US
Zhihao ZHA - Philadelphia PA, US
Futao LIU - Philadelphia PA, US
Karl PLOESSL - Wilmington DE, US
Seok Rye CHOI - Aston PA, US
Hank F. KUNG - Springfield PA, US
Assignee:
Five Eleven Pharma Inc. - Philadelphia PA
International Classification:
A61K 51/04
A61B 6/03
C07B 59/00
C07D 221/06
C07D 213/64
C07D 405/04
C07C 217/80
C07D 471/04
C07C 323/37
Abstract:
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Novel Deuterium Substituted Positron Emission Tomography (Pet) Imaging Agents And Their Pharmacological Application

View page
US Patent:
20180344882, Dec 6, 2018
Filed:
May 31, 2018
Appl. No.:
15/994474
Inventors:
- Philadelphia PA, US
Zhihao ZHA - Philadelphia PA, US
Futao LIU - Philadelphia PA, US
Karl PLOESSL - Wilmington DE, US
Seok Rye CHOI - Aston PA, US
Hank F. KUNG - Springfield PA, US
International Classification:
A61K 51/04
A61B 6/03
C07B 59/00
C07D 221/06
Abstract:
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Urea-Based Prostate Specific Membrane Antigen (Psma) Inhibitors For Imaging And Therapy

View page
US Patent:
20170189568, Jul 6, 2017
Filed:
Dec 20, 2016
Appl. No.:
15/385490
Inventors:
- Philadelphia PA, US
Karl PLOESSL - Wilmington DE, US
Seok Rye CHOI - Aston PA, US
Zhihao ZHA - Philadelphia PA, US
Zehui WU - Philadelphia PA, US
International Classification:
A61K 51/04
C07K 5/02
Abstract:
The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [Ga]GaClwith high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
Control profile
Karl H Ploessl from Wilmington, DE, age ~64 Get Report